Phasebio Pharmaceuticals Stock Debt To Equity

PHASQDelisted Stock  USD 0.0003  0.0001  25.00%   
PhaseBio Pharmaceuticals fundamentals help investors to digest information that contributes to PhaseBio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of PhaseBio Pink Sheet. The fundamental analysis module provides a way to measure PhaseBio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PhaseBio Pharmaceuticals pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

PhaseBio Pharmaceuticals Company Debt To Equity Analysis

PhaseBio Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

According to the company disclosure, PhaseBio Pharmaceuticals has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The debt to equity for all United States stocks is 100.0% higher than that of the company.

PhaseBio Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PhaseBio Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of PhaseBio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing PhaseBio Pharmaceuticals by comparing valuation metrics of similar companies.
PhaseBio Pharmaceuticals is currently under evaluation in debt to equity category among its peers.

PhaseBio Fundamentals

About PhaseBio Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze PhaseBio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PhaseBio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PhaseBio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with PhaseBio Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PhaseBio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PhaseBio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to PhaseBio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PhaseBio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PhaseBio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PhaseBio Pharmaceuticals to buy it.
The correlation of PhaseBio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PhaseBio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PhaseBio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PhaseBio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Consideration for investing in PhaseBio Pink Sheet

If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Commodity Directory
Find actively traded commodities issued by global exchanges
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device